Literature DB >> 15367253

Comparing medications in a therapeutic area using an NNT model.

J Jaime Caro1, K Jack Ishak, Ingrid Caro, Kristen Migliaccio-Walle, Wendy S Klittich.   

Abstract

OBJECTIVES: Clinicians are told to use the number needed to treat (NNT) to compare the benefits of therapeutic strategies, and researchers are asked to report results this way, generally without considering differences among the studies from which these were derived.
METHODS: The crude NNT currently advocated is compared to the NNT standardized for a common outcome, follow-up time, study population and comparator. An NNT model for cardiovascular disease is described as an example that addresses differences among studies of secondary prevention of cardiovascular disease. Crude NNTs are compared to those obtained from the model.
RESULTS: Follow-up in the 18 trials identified varied from 1.0 to 6.2 years; rates of cardiovascular events in the untreated subgroups ranged from 4.8% to 45.9%. The crude NNTs were more variable (9.1-163.7) than those obtained from the model (9.1-75.2). The effect of standardization was substantial in some cases, with proportional changes ranging from a 91% decrease to a 223% increase.
CONCLUSION: Using an NNT model to account for differences in study design allows for more meaningful comparisons.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15367253     DOI: 10.1111/j.1524-4733.2004.75009.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  3 in total

Review 1.  Clinical and public health assessment of benefits and risks of statins in primary prevention of coronary events: resolved and unresolved issues.

Authors:  Yola Moride; Robert A Hegele; Anatoly Langer; Ruth McPherson; David B Miller; Stéphane Rinfret
Journal:  Can J Cardiol       Date:  2008-04       Impact factor: 5.223

2.  The "number needed to treat" turns 20--and continues to be used and misused.

Authors:  Finlay A McAlister
Journal:  CMAJ       Date:  2008-09-09       Impact factor: 8.262

3.  Amikacin liposome inhalation suspension clinical benefit-risk assessment for refractory Mycobacterium avium complex lung disease.

Authors:  Theodore K Marras; Mariam Hassan; Kevin C Mange; Monika Ciesielska; Shilpa Dhar Murthy; Zhanna Jumadilova; Anjan Chatterjee
Journal:  ERJ Open Res       Date:  2022-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.